查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403379

臨床前CRO（委外研發機構）市場至2030年的預測：按模型類型、服務、動物模型、最終用戶和地區進行的全球分析

Preclinical Contract Research Organization Market Forecasts to 2030 - Global Analysis By Model Type, Service, Animal Model, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球臨床前CRO（委外研發機構）市場規模達到49.9億美元，預測期內年複合成長率為9.5%，預計到2030年將達到94.2億美元。

臨床前委外研發機構（CRO）是製藥和生物技術行業的專業服務供應商，在實驗藥物和治療方法進入臨床試驗之前對其進行研究和測試。臨床前 CRO 提供廣泛的服務來評估新化合物的安全性、有效性和風險。此外，臨床前 CRO 的知識和資源可以透過提供關鍵資訊和監管支援以及遵守監管和行業規範來幫助最佳化藥物開發。

根據IFPMA2021年報告，國際生物製藥產業的年度研發支出比航太和國防工業高7.3倍，比化學工業高6.5倍，比軟體和電腦服務業高出1.5倍。

全球化進程

CRO 是國際業務，為製藥和生技公司提供多個司法管轄區的廣泛資源、知識和監管管道。透過利用監管優勢、多樣化的患者群體和新興市場，公司可以透過全球化最佳化其藥物開發策略。此外，透過促進合作和創新以及加快新藥的上市時間和效率，可以改善醫療保健成果並改善公眾獲得尖端治療的機會。

高成本

遵守嚴格法規和維持品質標準的需要增加了費用。為了正確地進行臨床前研究，CRO 必須投入大量資金購買最先進的設施、機械和高素質的員工。激烈的競爭對 CRO 來說是常見的，提高了市場競爭的價格和業務開拓。此外，由於這些高昂的成本，小型或新的 CRO 可能很難進入市場，阻礙市場成長。

技術進步

製藥和生物技術公司可以利用先進技術做出更好的藥物開發決策。 CRO 利用這些特定知識來降低開發風險，加快識別有前途的候選藥物，並提高新治療方法的整體品質和安全性。此外，CRO 的專業知識和經驗使他們成為在嚴格的政府監管範圍內推動藥物開發和創新，擴大市場規模的有利盟友。

嚴格的法規環境

在這一領域營運的 CRO 面臨複雜法律規範的挑戰，這可能導致合規成本增加和計劃進度延遲。嚴格的法規環境也會影響製藥和生技公司選擇 CRO 合作夥伴時的決策流程。此外，監管負擔導致核准流程延長和檢查增加，影響 CRO 進行臨床前研究的整體有效性和進度。這種不利的環境抑制了創新，降低了臨床前研究服務的可用性，並抑制了市場擴張。

COVID-19 的影響

COVID-19的疫情對臨床前CRO（委外研發機構）市場產生了顯著的負面影響。延遲或取消的臨床前試驗數量減少了對 CRO 服務的需求。疫情造成的財務不確定性減少了研發投資，影響了為外包臨床前測試預留的資金。此外，景氣衰退和疫情造成的不確定性導致一些客戶推遲或取消臨床前研究，影響了CRO收益和成長前景，進一步阻礙了該市場。

預計預測期內毒理學測試領域規模最大

預計毒理學檢測領域將佔據最大佔有率。專門從事毒理學的 CRO 透過徹底評估潛在藥物以滿足嚴格的監管標準，為生物技術和製藥公司提供關鍵服務。這些測試透過評估化學物質如何影響各種生物系統來幫助發現不良反應和給藥。因此，透過最大限度地降低開發風險，加快監管核准和確保藥物安全來保護公共衛生和藥物開發舉措的成功，推動該領域的成長。

患者來源的異質骨移植（PDX）領域預計在預測期內年複合成長率最高

患者來源的異質骨移植（PDX）領域預計在預測期內年複合成長率最高。這是由於 PDX 模型，將患者的腫瘤組織移植到免疫力缺乏小鼠體內，以重建患者的腫瘤環境。如果候選藥物在更臨床相關的環境中進行評估，這些模型更有可能在人體試驗中取得成功。此外，PDX CRO 還提供個體化醫療見解，為特定患者提供治療。由於精準醫療的重要性日益增加，PDX 市場對於進一步開發高效、有針對性的癌症治療非常重要，推動了這一領域的擴張。

佔有率最大的地區

由於促進製藥公司和 CRO 之間順利資料交換和協作的整合平台的成長，亞太地區在預測期內獲得了最大的市場佔有率。 Covance Inc.、Medpace Holdings, Inc.、MPI Research 和 Eurofins Scientific 等主要企業為國際合作提供了有吸引力的環境，並為全球製藥和生物技術行業的發展做出了貢獻。此外，政府支持的增加，監管的協調以及高通量篩檢，機器學習和資料處理人工智慧等技術進步推動該地區的擴張。

年複合成長率最高的地區：

鑑於北美在藥物開發臨床前階段對支持製藥和生物技術公司的關鍵作用，預計在預測期內年複合成長率最高。美國、加拿大和墨西哥地區的特點是強大的基礎設施、最尖端科技和高技能的勞動力。這些領域包括藥理學、毒理學、生物分析以及對監管核准非常重要的各種其他臨床前研究。此外，該地區的 CRO 受益於有利的法規環境以及與學術機構的合作，促進創新和專業知識，並支持該地區的成長。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球臨床前CRO（委外研發機構）市場：依模型類型

  • 患者異質骨移植（PDX）
  • 患者來源的類器官（PDO）

第6章 全球臨床前 CRO（委外研發機構）市場：依服務分類

  • 安全藥理學
  • 生物分析以及藥物代謝和藥物動力學 (DMPK) 研究
    • 體外藥物動力學（PK）
    • 體內藥物動力學（PK）
  • 毒性試驗
  • 化學
    • 計算化學
    • 藥物化學
  • 複合管理
    • 製程研發
    • 自訂合成
    • 其他綜合管理
  • 其他服務

第7章 全球臨床前CRO（委外研發機構）市場：依動物模型

  • 大型動物模型
  • 小型動物模型

第8章 全球臨床前 CRO（委外研發機構）市場：依最終使用者分類

  • 政府和學術機構
  • 醫療設備公司
  • 生物製藥公司
  • 其他最終用戶

第9章 全球臨床前CRO（委外研發機構）市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Crown Bioscience
  • Eurofins Scientific
  • Laboratory Corporation of America, Inc.
  • PRA Health Sciences, Inc.
  • Intertek Group Plc（IGP）
  • Wuxi AppTec
  • SGS SA（SGS）
  • Medpace, Inc.
  • Pharmaceutical Product Development（PPD）, LLC
  • Charles River Laboratories International, Inc.
  • PPD（Thermo Fisher Scientific, Inc.）
  • WuXi AppTec, Inc.（WAI）
Product Code: SMRC24604

According to Stratistics MRC, the Global Preclinical Contract Research Organization (CRO) Market is accounted for $4.99 billion in 2023 and is expected to reach $9.42 billion by 2030 growing at a CAGR of 9.5% during the forecast period. A Preclinical Contract Research Organization (CRO) is a specialized service provider in the pharmaceutical and biotechnology industry that conducts research and testing on experimental drugs and therapies before they enter clinical trials. To evaluate the safety, efficacy, and possible dangers associated with novel compounds, preclinical CROs provide a broad range of services. Furthermore, their knowledge and resources aid pharmaceutical businesses in optimizing drug development by offering vital information and regulatory support and by providing adherence to regulatory and industry norms.

According to the IFPMA's 2021 report, the annual R&D spending by the international biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Increase in globalization

CROs are international businesses that provide pharmaceutical and biotech firms with access to a wide range of resources, knowledge, and regulatory routes in several jurisdictions. By taking advantage of regulatory benefits, diversified patient populations, and developing markets, corporations can optimize their drug development strategy through globalization. Additionally, it improves healthcare outcomes and public access to cutting-edge therapeutics by encouraging cooperation and innovation and accelerating the time and efficiency of bringing new drugs to market.

Restraint:

High cost

The need to adhere to stringent regulatory regulations and uphold quality standards increases expenditures. To properly undertake preclinical research, CROs must invest a significant amount of money in cutting-edge facilities, machinery, and highly qualified staff. Intense competition is a common occurrence for CROs, which raises the price of marketing and business development initiatives. In addition, smaller or newly established CROs may find it difficult to enter the market due to these exorbitant costs, which thereby hinder market growth.

Opportunity:

Technological advancements

Pharmaceutical and biotech businesses may make well-informed judgments on drug development with the help of their advanced technologies, which enables them to provide reliable and efficient preclinical testing and data analysis. CROs use this specific knowledge to lower development risks, speed up the identification of promising drug candidates, and improve the general quality and safety of novel treatments. Furthermore, because of their specialization and experience, CROs are advantageous collaborators for promoting drug development and innovation in a tough, government-regulated setting thereby driving this market size.

Threat:

Stringent regulatory environment

CROs operating in this space encounter challenges in navigating the intricate regulatory frameworks, leading to increased compliance costs and potential delays in project timelines. The stringent regulatory environment also influences the decision-making process of pharmaceutical and biotechnology companies when selecting CRO partners. Furthermore, the regulatory load results in longer approval processes and more inspection, affects the general effectiveness and pace of preclinical research carried out by CROs. This unfavourable environment inhibits innovation, lowers the availability of preclinical research services, and thereby impedes this market expansion.

COVID-19 Impact

The COVID-19 pandemic has had a notable negative impact on the preclinical contract research organization (CRO) market. The number of preclinical studies that were postponed or cancelled resulted in a decline in the need for CRO services. The pandemic's financial insecurity has resulted in decreased investment in research and development, which has an effect on the money set aside for preclinical study outsourcing. Furthermore, the pandemic-induced economic downturn and uncertainty prompted some clients to postpone or cancel preclinical projects, impacting the revenue and growth prospects of CRO and further impeding this market.

The toxicology testing segment is expected to be the largest during the forecast period

The toxicology testing segment is estimated to hold the largest share. Toxicology-focused CROs offer vital services to biotech and pharmaceutical firms by thoroughly assessing potential drugs in order to satisfy strict regulatory standards. These tests help discover harmful reactions and dosage levels by assessing how chemicals affect different biological systems. Therefore, it protects public health and the success of drug development initiatives by minimizing development risks, expediting regulatory approvals, and guaranteeing the safety of pharmaceutical goods, which thereby boosts this segment's growth.

The patient derived xenograft (PDX) segment is expected to have the highest CAGR during the forecast period

The patient derived xenograft (PDX) segment is anticipated to have highest CAGR during the forecast period due to the tumor tissues from patients being transplanted into immunodeficient mice in PDX models to replicate the tumor environment of the patient. These models show a greater chance of success in human trials when drug candidates are evaluated in a more clinically appropriate setting. Furthermore, customized medicine insights are provided by PDX CROs, enabling treatmentsfor specific patients. The PDX market is essential for further developing efficient and targeted cancer treatments because of the growing significance of precision medicine, thereby driving this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the growth of integrated platforms that facilitate smooth data exchange and cooperation between pharmaceutical corporations and CROs. Key players such as Covance Inc., Medpace Holdings, Inc., MPI Research, and Eurofins Scientific offer a compelling environment for international collaborations and are establishing themselves in advancing the global pharmaceutical and biotechnology industries. Additionally, growing government support, regulatory harmonization, and technological advancements such as high-throughput screening, machine learning, and artificial intelligence for data processing drive this region's expansion.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period, owing to its pivotal role in supporting pharmaceutical and biotechnology companies in the preclinical phase of drug development. The United States, Canada, and Mexico regions are characterized by a robust infrastructure, cutting-edge technology, and a highly skilled workforce. They include pharmacology, toxicology, bioanalysis, and various other preclinical studies essential for regulatory approval. Furthermore, the region's CROs benefit from a favorable regulatory environment and collaboration with academic institutions, fostering innovation and expertise that are propelling this region's growth.

Key players in the market:

Some of the key players in the Preclinical Contract Research Organization (CRO) Market include Crown Bioscience, Eurofins Scientific, Laboratory Corporation of America, Inc., PRA Health Sciences, Inc., Intertek Group Plc (IGP), Wuxi AppTec, SGS SA (SGS), Medpace, Inc., Pharmaceutical Product Development (PPD), LLC, Charles River Laboratories International, Inc., PPD (Thermo Fisher Scientific, Inc.) and WuXi AppTec, Inc. (WAI).

Key Developments:

In November 2023, Intertek, announced the launch of iCare in Turkiye, one of its most successful markets. iCare is an innovative one-stop digital portal providing textile manufacturers with a pioneering solution that enables seamless management and monitoring of their testing processes from start to finish.

In October 2023, SGS is signed an agreement to divest its US powertrain testing operations as part of its strategic portfolio evolution to Columbia River Partners, a private equity firm focused on the industrials, business services and IT services sectors, headquartered in California.

In September 2023, Intertek, proudly announced the integration of advanced PhotonAssay technology into its Minerals laboratory facility in Tarkwa, Ghana. With a legacy of excellence and a commitment to innovation, Intertek Minerals aims to revolutionise gold industry support in West Africa through the implementation of this groundbreaking technology.

Model Types Covered:

  • Patient Derived Xenograft (PDX)
  • Patient Derived Organoid (PDOs)

Services Covered:

  • Safety Pharmacology
  • Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
  • Toxicology Testing
  • Chemistry
  • Compound Management
  • Other Services

Animal Models Covered:

  • Large Animal Model
  • Small Animal Model

End Users Covered:

  • Government and Academic Institutes
  • Medical Device Companies
  • Biopharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preclinical Contract Research Organization (CRO) Market, By Model Type

  • 5.1 Introduction
  • 5.2 Patient Derived Xenograft (PDX)
  • 5.3 Patient Derived Organoid (PDOs)

6 Global Preclinical Contract Research Organization (CRO) Market, By Service

  • 6.1 Introduction
  • 6.2 Safety Pharmacology
  • 6.3 Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies
    • 6.3.1 In vitro Pharmacokinetics (PK)
    • 6.3.2 In-vivo Pharmacokinetics (PK)
  • 6.4 Toxicology Testing
  • 6.5 Chemistry
    • 6.5.1 Computation Chemistry
    • 6.5.2 Medicinal Chemistry
  • 6.6 Compound Management
    • 6.6.1 Process R&D
    • 6.6.2 Custom Synthesis
    • 6.6.3 Other Compound Managements
  • 6.7 Other Services

7 Global Preclinical Contract Research Organization (CRO) Market, By Animal Model

  • 7.1 Introduction
  • 7.2 Large Animal Model
  • 7.3 Small Animal Model

8 Global Preclinical Contract Research Organization (CRO) Market, By End User

  • 8.1 Introduction
  • 8.2 Government and Academic Institutes
  • 8.3 Medical Device Companies
  • 8.4 Biopharmaceutical Companies
  • 8.5 Other End Users

9 Global Preclinical Contract Research Organization (CRO) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Crown Bioscience
  • 11.2 Eurofins Scientific
  • 11.3 Laboratory Corporation of America, Inc.
  • 11.4 PRA Health Sciences, Inc.
  • 11.5 Intertek Group Plc (IGP)
  • 11.6 Wuxi AppTec
  • 11.7 SGS SA (SGS)
  • 11.8 Medpace, Inc.
  • 11.9 Pharmaceutical Product Development (PPD), LLC
  • 11.10 Charles River Laboratories International, Inc.
  • 11.11 PPD (Thermo Fisher Scientific, Inc.)
  • 11.12 WuXi AppTec, Inc. (WAI)

List of Tables

  • Table 1 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 3 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 4 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 5 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 6 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 7 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 8 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 9 Global Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 10 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 11 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 12 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 13 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 14 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 15 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 16 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 17 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 18 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 19 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 20 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 21 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 22 Global Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 24 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 25 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 26 Global Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 27 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 28 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 29 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 30 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 31 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 32 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 33 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 34 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 35 North America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 36 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 37 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 38 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 39 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 40 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 41 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 42 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 43 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 44 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 45 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 46 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 47 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 48 North America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 50 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 51 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 52 North America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 53 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 54 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 55 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 56 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 57 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 58 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 59 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 60 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 61 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 62 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 63 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 64 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 65 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 66 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 67 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 68 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 69 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 70 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 71 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 72 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 73 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 74 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 76 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 77 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 78 Europe Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 79 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 80 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 81 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 82 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 83 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 84 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 85 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 86 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 87 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 88 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 89 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 90 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 91 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 92 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 93 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 94 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 95 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 96 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 97 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 98 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 99 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 100 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 101 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 102 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 103 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 104 Asia Pacific Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 105 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 106 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 107 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 108 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 109 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 110 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 111 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 112 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 113 South America Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 114 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 115 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 116 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 117 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 118 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 119 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 120 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 121 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 122 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 123 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 124 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 125 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 126 South America Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 127 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 128 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 129 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 130 South America Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 131 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Country (2021-2030) ($MN)
  • Table 132 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Model Type (2021-2030) ($MN)
  • Table 133 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Xenograft (PDX) (2021-2030) ($MN)
  • Table 134 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Patient Derived Organoid (PDOs) (2021-2030) ($MN)
  • Table 135 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Service (2021-2030) ($MN)
  • Table 136 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Safety Pharmacology (2021-2030) ($MN)
  • Table 137 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies (2021-2030) ($MN)
  • Table 138 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In vitro Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 139 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By In-vivo Pharmacokinetics (PK) (2021-2030) ($MN)
  • Table 140 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Toxicology Testing (2021-2030) ($MN)
  • Table 141 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Chemistry (2021-2030) ($MN)
  • Table 142 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Computation Chemistry (2021-2030) ($MN)
  • Table 143 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medicinal Chemistry (2021-2030) ($MN)
  • Table 144 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Compound Management (2021-2030) ($MN)
  • Table 145 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Process R&D (2021-2030) ($MN)
  • Table 146 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Custom Synthesis (2021-2030) ($MN)
  • Table 147 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Compound Managements (2021-2030) ($MN)
  • Table 148 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other Services (2021-2030) ($MN)
  • Table 149 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Animal Model (2021-2030) ($MN)
  • Table 150 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Large Animal Model (2021-2030) ($MN)
  • Table 151 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Small Animal Model (2021-2030) ($MN)
  • Table 152 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By End User (2021-2030) ($MN)
  • Table 153 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Government and Academic Institutes (2021-2030) ($MN)
  • Table 154 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Medical Device Companies (2021-2030) ($MN)
  • Table 155 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Biopharmaceutical Companies (2021-2030) ($MN)
  • Table 156 Middle East & Africa Preclinical Contract Research Organization (CRO) Market Outlook, By Other End Users (2021-2030) ($MN)